No histology report on its own justifies dispensing this product; a molecular result does. Crizotinib 250 mg tablets, marketed as Crizonix, are written for narrowly defined subgroups carved out by genomic testing, and each subgroup rests on a different rearrangement or splice alteration.
Three distinct oncogenic drivers plus one rare soft-tissue tumour type share access to the same 250 mg tablet, which makes patient identification — not dose selection — the decisive clinical step for this molecule.
The tablet delivers a multi-target tyrosine kinase inhibitor with meaningful affinity for three related receptors: ALK, ROS1 and MET. Each becomes pathogenic through a different accident. ALK and ROS1 are activated by chromosomal fusion, in which a partner gene supplies a dimerisation domain and the kinase begins firing without instruction. MET follows another route entirely — a splice-site mutation deletes exon 14, removing the docking site that recruits the ubiquitin ligase responsible for degrading the receptor, so a normal protein simply survives far too long.
One compound covers all three because their catalytic domains share enough structural resemblance to accept a common inhibitor. Clinically this means one supply line serves several biomarker-defined cohorts.
Registered use covers ALK-positive advanced non-small cell lung cancer and ROS1-rearranged NSCLC. Separately, the agent is used in inflammatory myofibroblastic tumour, a rare mesenchymal neoplasm in which ALK rearrangement is frequent and which appears disproportionately in children and young adults — a population rarely served by targeted oncology at all. MET exon 14 skipping defines a further cohort, typically older patients with a heavier smoking history than the fusion groups.
The standard adult schedule is 250 mg twice daily, roughly twelve hours apart, with or without food. Capsule-shaped tablets are swallowed intact. Grapefruit and grapefruit juice are excluded because CYP3A inhibition raises exposure. Paediatric use in inflammatory myofibroblastic tumour is dosed on body surface area rather than by the flat adult figure. Ophthalmic symptoms, transaminase elevation and bradycardia are monitored on schedule. Prescribing decisions rest with the treating specialist.
Ambient storage below 30 °C in the sealed original pack is sufficient; no cold chain applies. Because therapy is continuous, purchasers generally forecast against months of uninterrupted supply rather than single dispensing events.
Q: Which laboratory methods establish eligibility before this tablet is prescribed?
A: Break-apart FISH, validated immunohistochemistry or an NGS fusion panel confirms ALK or ROS1; RNA-based sequencing is the dependable way to call MET exon 14 skipping.
Q: Do the three biomarker cohorts differ in clinical profile?
A: Considerably. Fusion-positive patients skew younger and frequently never-smokers, while the MET exon 14 group is typically older with substantial tobacco exposure.
Q: Why is this agent used in a rare tumour outside the lung?
A: Inflammatory myofibroblastic tumour carries ALK rearrangement in a large share of cases, so the same target exists in a completely different tissue lineage.
Q: Is the adult 250 mg twice-daily figure appropriate for younger patients?
A: No — paediatric dosing is calculated from body surface area, and the flat adult schedule should never be transferred across.
No histology report on its own justifies dispensing this product; a molecular result does. Crizotinib 250 mg tablets, marketed as Crizonix, are written for narrowly defined subgroups carved out by genomic testing, and each subgroup rests on a different rearrangement or splice alteration.
Three distinct oncogenic drivers plus one rare soft-tissue tumour type share access to the same 250 mg tablet, which makes patient identification — not dose selection — the decisive clinical step for this molecule.
The tablet delivers a multi-target tyrosine kinase inhibitor with meaningful affinity for three related receptors: ALK, ROS1 and MET. Each becomes pathogenic through a different accident. ALK and ROS1 are activated by chromosomal fusion, in which a partner gene supplies a dimerisation domain and the kinase begins firing without instruction. MET follows another route entirely — a splice-site mutation deletes exon 14, removing the docking site that recruits the ubiquitin ligase responsible for degrading the receptor, so a normal protein simply survives far too long.
One compound covers all three because their catalytic domains share enough structural resemblance to accept a common inhibitor. Clinically this means one supply line serves several biomarker-defined cohorts.
Registered use covers ALK-positive advanced non-small cell lung cancer and ROS1-rearranged NSCLC. Separately, the agent is used in inflammatory myofibroblastic tumour, a rare mesenchymal neoplasm in which ALK rearrangement is frequent and which appears disproportionately in children and young adults — a population rarely served by targeted oncology at all. MET exon 14 skipping defines a further cohort, typically older patients with a heavier smoking history than the fusion groups.
The standard adult schedule is 250 mg twice daily, roughly twelve hours apart, with or without food. Capsule-shaped tablets are swallowed intact. Grapefruit and grapefruit juice are excluded because CYP3A inhibition raises exposure. Paediatric use in inflammatory myofibroblastic tumour is dosed on body surface area rather than by the flat adult figure. Ophthalmic symptoms, transaminase elevation and bradycardia are monitored on schedule. Prescribing decisions rest with the treating specialist.
Ambient storage below 30 °C in the sealed original pack is sufficient; no cold chain applies. Because therapy is continuous, purchasers generally forecast against months of uninterrupted supply rather than single dispensing events.
Q: Which laboratory methods establish eligibility before this tablet is prescribed?
A: Break-apart FISH, validated immunohistochemistry or an NGS fusion panel confirms ALK or ROS1; RNA-based sequencing is the dependable way to call MET exon 14 skipping.
Q: Do the three biomarker cohorts differ in clinical profile?
A: Considerably. Fusion-positive patients skew younger and frequently never-smokers, while the MET exon 14 group is typically older with substantial tobacco exposure.
Q: Why is this agent used in a rare tumour outside the lung?
A: Inflammatory myofibroblastic tumour carries ALK rearrangement in a large share of cases, so the same target exists in a completely different tissue lineage.
Q: Is the adult 250 mg twice-daily figure appropriate for younger patients?
A: No — paediatric dosing is calculated from body surface area, and the flat adult schedule should never be transferred across.
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
